XOLREMDI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XOLREMDI (XOLREMDI).
Givosiran is a small interfering RNA (siRNA) that targets the 5-aminolevulinic acid synthase 1 (ALAS1) mRNA. By degrading ALAS1 mRNA, it reduces the hepatic production of the enzyme ALAS1, thereby decreasing the levels of neurotoxic heme precursors (aminolevulinic acid and porphobilinogen) that accumulate in acute hepatic porphyria.
| Metabolism | Givosiran is metabolized by nucleases to oligonucleotides of shorter lengths. It is not a substrate for cytochrome P450 enzymes. |
| Excretion | Primarily via renal excretion of unchanged drug (approximately 60-70%) and fecal/biliary elimination (30-40%) as metabolites. |
| Half-life | Terminal elimination half-life is approximately 20-24 hours in adults, allowing once-daily dosing; may be prolonged in renal impairment. |
| Protein binding | ~90% bound to serum albumin. |
| Volume of Distribution | Vd ≈ 1.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 60-70% (first-pass metabolism reduces absolute bioavailability). |
| Onset of Action | Oral: Therapeutic effect observed within 1-2 hours. |
| Duration of Action | Duration of action supports 24-hour dosing interval due to sustained plasma levels. |
| Molecular Weight | ~150,000 Da (monoclonal antibody) |
0.3 mg/kg intravenously every 3 weeks for 4 doses; continue with 0.3 mg/kg intravenously every 4 weeks for maintenance.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73m2) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Weight-based dosing: 0.3 mg/kg intravenously every 3 weeks for 4 doses, then 0.3 mg/kg intravenously every 4 weeks. Safety and efficacy not established in pediatric patients weighing <21 kg. |
| Geriatric use | No specific dose adjustment recommended; clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. |
| 1st trimester | No adequate human data; animal studies show no teratogenicity at clinically relevant doses. Use only if potential benefit justifies risk. |
| 2nd trimester | Limited data; no known fetal harm. Consider maternal benefit vs. unknown fetal risk. |
| 3rd trimester | No adverse fetal effects reported. Avoid use near term unless necessary due to lack of safety data. |
Clinical note
Comprehensive clinical and safety monograph for XOLREMDI (XOLREMDI).
| Placental transfer | Unknown; likely minimal due to high molecular weight. |
| Breastfeeding | No human data on transfer into breast milk. Manufacturer advises caution due to potential for adverse effects in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to active substance or any excipients
| Precautions | Renal toxicity: Monitor renal function before and during therapy; dose reduction or discontinuation may be required., Hepatotoxicity: Monitor liver function; elevations in transaminases and bilirubin have occurred., Infusion-related reactions: Administer with premedication; monitor during infusion., Immunogenicity: Development of anti-drug antibodies may occur; clinical significance unknown. |
| Food/Dietary | There are no known significant food interactions with XOLREMDI. The drug is administered subcutaneously and does not require dietary restrictions. Maintain a balanced diet as part of overall health management. |
Loading safety data…
| L3 (Limited Data) |
| Teratogenic Risk | XOLREMDI (vamorolone) is a corticosteroid analog. No adequate human data on fetal risk. In animal studies, administration during organogenesis resulted in increased fetal malformations (cleft palate, skeletal variations) and reduced fetal weight at doses similar to human exposure. First trimester: potential for malformations based on corticosteroid class effects. Second/third trimester: chronic exposure may cause fetal growth restriction, adrenal suppression, and possible preterm birth. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. For fetus, consider growth ultrasounds if chronic in utero exposure. Newborns exposed in utero: monitor for adrenal suppression and hypoglycemia. |
| Fertility Effects | No human data. In animal studies, vamorolone did not impair fertility at clinically relevant doses. Corticosteroid class may alter menstrual cycle or reduce sperm count, but specific effects for vamorolone are unknown. |
| Clinical Pearls | XOLREMDI (vutrisiran) is an RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. Administer subcutaneously every 3 months. Monitor for infusion reactions, which are rare but may include flushing, dyspnea, or rash. Premedication with antihistamines and corticosteroids is not required but may be considered for high-risk patients. Assess baseline liver function and monitor periodically; transaminase elevations have been reported. Do not use in patients with severe hepatic impairment. Efficacy was demonstrated in the HELIOS-A trial, showing improvement in neuropathy impairment scores. |
| Patient Advice | XOLREMDI is given as an injection under the skin every 3 months. · It is used to treat a specific type of amyloidosis that affects nerves. · Common side effects include injection site reactions (redness, pain, swelling), nausea, and headache. · Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or persistent nausea. · Avoid pregnancy while on treatment; use effective contraception. · Do not confuse XOLREMDI with other similar-sounding medications. |